Alpha Tau Medical’s Alpha DaRT treatment employs localized alpha radiation delivered directly into tumors, demonstrating 100% tumor response in early FDA trials across multiple solid tumor types, including pancreas and glioblastoma. Remarkably, the therapy induces systemic immune responses resulting in regression of untreated tumors elsewhere, as evidenced by both patient cases and animal models. Recent combination trials with pembrolizumab immunotherapy reported significant enhancement of therapeutic response rates, with complete response rates rising from 5% to 37.5%. The treatment has received multiple FDA designations, including breakthrough device status, underscoring its potential in oncology.